Doctor of Osteopathy Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Keith Freeman

Internal Medicine Greenville, SC Doctor of Osteopathy

NPI 1003357948 CMS profile 7403757

10 Enterprise Blvd Ste 110, Greenville, SC 29615

Open in the dashboard

General payments

$2,167

132 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Keith Freeman of Greenville, SC is reported in the CMS Open Payments database as having received $2,167 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $31 2
2023 General $521 29
2022 General $664 40
2021 General $699 46
2020 General $251 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Freeman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Keith Freeman were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Keith Freeman Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $251 $119 $33–$402 $114
2021 $699 $135 $37–$521 $132
2022 $664 $141 $42–$496 $149
2023 $521 $149 $45–$519 $160
2024 $31 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. Novo Nordisk Inc $347 21 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $332 21 payments
  3. Dexcom, Inc. $264 14 payments
  4. AbbVie, Inc. $198 13 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $104 7 payments
  6. AstraZeneca Pharmaceuticals LP $90 7 payments
  7. Amgen Inc. $85 4 payments
  8. Daiichi Sankyo Inc. $78 4 payments
  9. Lilly USA, LLC $77 5 payments
  10. Sanofi-Aventis U.S. LLC $66 4 payments
  11. Other $526 32 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Food and Beverage $2,167 132 payments
Products named General payments · program years 2020–2024
  1. RYBELSUS $305 18 payments
  2. Ozempic $290 17 payments
  3. Dexcom G6 Transmitter $214 11 payments
  4. JARDIANCE $208 14 payments
  5. TRADJENTA $110 8 payments
  6. Kerendia $104 7 payments
  7. STIOLTO RESPIMAT $104 6 payments
  8. SYNJARDY $94 7 payments
  9. FARXIGA $90 7 payments
  10. AIMOVIG $85 4 payments
  11. Other $1,439 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

6,213

Median for Internal Medicine: 777

Drug cost

$440,423

Median for Internal Medicine: $73,373

Branded share of claims

16.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 74 $106,322
Ozempic Semaglutide Brand 55 $88,031
Eliquis Apixaban Brand 36 $39,511
Januvia Sitagliptin Phosphate Brand 19 $28,276
Farxiga Dapagliflozin Propanediol Brand 20 $22,933
Xarelto Rivaroxaban Brand 24 $22,804
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $19,293
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $12,247
Repatha Sureclick Evolocumab Brand 11 $11,079
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 41 $5,327

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$83,779

Of which drugs: $3,881

Medicare patients

349

Average age 76

Services billed

1,306

165 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 42%
Ischemic heart disease 35%
Depression 26%
Diabetes 21%
Chronic kidney disease 20%
Atrial fibrillation 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 26 26 $2,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record